2 0 1 8
PCI Pharma’s game-changing digital platform
The pharmaceutical industry has historically been risk averse and slow to adopt technology. PCI Pharma Services is blazing a trail in digitalisation. “PCI Pharma Services is recognised in the industry as a leader when it comes to providing world-class customer service,” said Wayne Hull, Global Chief Digital and Technology Officer, PCI. “In order to retain that leadership position going forward, digital experiences and capabilities are essential.”
PCI is now two years into a three-year corporate digital transformation strategy that is already differentiating the company, and providing real and measurable returns – the pci | bridge platform is a prime example of this. pci | bridge gives customers real-time visibility into their clinical and commercial supply chain to enable closer collaboration with PCI’s teams and provide instantaneous data and insights to inform decision-making. “We wanted to build a very customercentric, user experience (UX) platform with information that is relevant to customers’ projects and their relationship with PCI,” said Morgan Brandt, Director, Digital Products, PCI. “We also want to provide as much transparency as possible, saving time and resources to ultimately help bring lifechanging therapies to patients faster.”
Addressing clinical trial management needs Clinical trial services is the fastest-growing and most logistics-heavy division at PCI. Clinical trial activity intensified further during the coronavirus pandemic, with a greater demand for new COVID-19 tests and therapies. While pci | bridge was not developed specifically in response to COVID-19, PCI had to scale up to meet the moment. “COVID-19 highlighted a need we were already focused on” said Tim Roberts, Vice President for Global Sales for Clinical Services, PCI. “The level of detail in the platform is a big differentiator. Users can easily navigate among clinical trials and drill down into deep layers of data to maximise transparency.” The platform helps customers to better manage the clinical trials process from start to finish, from shipments to temperature control, with seamless functionality. A key feature of pci | bridge is its ability to pull in real-time data across inventory, production and distribution.
Built from the outside in PCI wanted to go beyond data to create a consistent yet technologically leading platform built around the entire customer experience. PCI worked with customers to illuminate their desires for a better way to work together, such as more supply chain visibility and less time spent on manual activity to manage the PCI relationship. “The benefits of using pci | bridge is that is that it eliminates the need for clients to constantly reach out to the project teams for
updates,” said Kevin Gregorczyk, Director, Development Operations at eFFECTOR Therapeutics, which participated in the development process. “Now, we will have that information at our fingertips and can instead focus on the bigger picture with PCI, such as what’s coming next.”
The digital journey continues While clinical trials are often the entry point for PCI customers, pci | bridge can be used throughout the product lifecycle. The company is continuing to invest and enhance the platform with more integrations and other expanded functionality. For example, PCI plans to integrate pci | bridge into systems customers already use, such as interactive response technology (IRT) systems – an essential component of clinical trial management.
“We are always looking to the future and can see the potential that digitisation holds for the pharma and biopharma supply chain,” said Wayne. “pci | bridge is a leading-edge client experience that will continue to evolve as the business requires. Ultimately, if you work in 10 systems, we want to eliminate nine so you only have to use one resource for a seamless experience.”
www.pci.com
39
